Preeclampsia의 최신 지견

참고문헌 (82)

1. Sibai BM, "What have learned about preeclampsia?", 27, pp.239~246 (2003)
2. Walker JJ, "Pre-eclampsia", 356, pp.1260~1265 (2000)
3. Karumanchi SA, "Pathogenesis of Preeclampsia" (2004)
4. Roberts JM, "Pathogenesis and genetics of pre-eclampsia", 357, pp.53~56 (2001)
5. Roberts JM, "Preeclampsia:what we know and what we know and what we do not know", 24, pp.24~28 (2000)
6. Roberts JM, "Endothelial dysfunction in preeclampsia", 16, pp.5~15 (1998)
7. Roberts JM, "Preeclampsia:an endothelial cell disorder", 161, pp.1200~4 (1989)
8. Page EW, "The relation between hydatid moles relative ischemia of the gravid uterus and the placental origin of eclampsia", pp.291~3
9. De Wolf F, "Brosens I The ultrastructure of acute atherosis in hypertensive pregnancy", pp.164~74
10. Khong TY, "Inadequate maternal vascular response to placentation in pregnancies complicated by pre- eclampsia and by small-for-gestational age infants", 93, pp.1049~59 (1986)
11. Robertson WB, "The pathological response of the vessels of the placental bed to hypertensive pregnancy J Pathol Bacteriol 1967", pp.581~92
12. Gerretsen G, "Mor-phological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation", 88, pp.876~81 (1981)
13. Dekker GA, "Risk factors for preeclampsia", 42, pp.422~435 (1999)
14. Casper FW, "Atrial natriuretic pep-tide (ANP) in preeclampsia-like syndrome in a rat model", 103, pp.292~296 (1995)
15. Kumar D, "Chronic placental ischemia in relation to toxemias of preg nancy", pp.1323~9
16. Brosens IA, "The role of the spiral arteries in the pathogen-esis of preeclampsia", 1, pp.177~91 (1972)
17. Genbacev O, "Hypoxia alters early gestation human cyto-trophoblast differentiation", invasion in vitro and models the placental defects that occur in preeclampsia, 1996, pp.97, 540~550
18. Genbcev O, "Regulation of human placental development by oxygen tension", 277, pp.1669~1672 (1997)
19. Damsky CH, "Distribution patterns of extrace llular matrix components and adhesion receptors are intricately modul ated during first trimester cytotrophoblast differentiation along the in vasive pathway", pp.210~22
20. Damsky CH, "integrin switching regulates normal tropho-blastinvasion", 120, pp.3657~66 (1994)
21. Fisher SJ, "Human cytotrophoblast invasion", 4, pp.183~8 (1993), Semin Cell Biol
22. Zhou Y, "Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?", 99, pp.2139~2151 (1997)
23. Zhou Y, "Preeclampsia is associated with fail ure of human cytotro-phoblasts to mimic a vascular adhesion pheno- type. One cause of defective endovascular invasion in this syndrome?", 99, pp.2152~2164 (1997)
24. Zhou Y, "Pre-eclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophob lasts", 91, pp.950~60 (1993)
25. Zhou Y, "The human placenta remodels the uterus by using a com-bination of molecules that govern vasculo- genesis or leukocyte extravasation", 995, pp.73~83 (2003)
26. Zhou Y, "Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver en-zymes, and low platelets syndrome", 160, pp.1405~1423 (2002)
27. Friedman SA, "Biochemical corroboration of endothelial involvement in severe preeclampsia", 172, pp.202~203 (1995)
28. Hsu CD, "Elevated circulating thrombomodulin in severe pre-eclampsia", 169, pp.148~9 (1993)
29. Taylor RN, "High plasma cellular bro-nectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone", 165, pp.895~901 (1991)
30. Cockell AP, "Flow-mediated vaso-dilatation is enhanced in normal pregnancy but reduced in preeclampsia", 30, pp.247~251 (1997)
31. McCarthy AL, "Abnormal endothelial cell function of resistance arteries from women with preeclamp-sia", 168, pp.1323~30 (1993)
32. Savvidou MD, "Endothelial dysfunction and raised plasma concentrations of asymmetric dime-thylarginine in pregnant women who subsequently develop pre-eclampsia", 361, pp.1511~1517 (2003)
33. Mills JL, "Prostacyclin and thromb oxane changes predating clinical onset of preeclampsia: a mul-ticenter prospective study", 282, pp.356~362 (1999)
34. Gant NF, "A study of angiotensin II pressor response through-out primigravid pregnancy", 52, pp.2682~9 (1973)
35. Clark BA, "Plasma endothelin levels in preeclampsia:elevation and correlation with uric acid levels and renal impairment", 166, pp.962~8 (1992)
36. Fisher KA, "Hypertension in pregnancy", pp.267~76 (1981), clinincal-pathological correlations and remote prognosis
37. Roberts JM, "Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro:morphological and biochemical evidence", 27, pp.101~8 (1992)
38. Benyo DF, "Expression of inflam- matory cytokines in placentas from women with preeclampsia", 86, pp.2505~2512 (2001)
39. Conran KP, "Circulating levels of immunore- active cytokines in women with preeclampsia", 40, pp.102~111 (1998)
40. Page NM, "Excessive placental secretion of neurokinin B during the third trimester causes preeclampsia", 405, pp.797~800 (2000)
41. Wallukat G, "patients with preeclampsia develop agonistic autoantibodies against the angiotensin AII receptor", 103, pp.945~952 (1999)
42. Dechend R,, "AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor", 101, pp.2382~2387 (2000)
43. Dechend R, "AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxi-dase", 107, pp.1632~1639 (2003)
44. Maynard SE, "Excess placental soluble fms- like tyrosine kinase 1 may contribute to endothelial dysfunction, hypertension, and proteinuria preecampsia", 111, pp.649~658 (2003)
45. Dvorak HF, "Vascular permeability factor", vascular endothelial growth factor:a critical cytokine in tumor angiogenesis and a poton-tial target for diagnosis and therapy, 2002, pp.20, 4368~4380
46. Kendall RL, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor", 90, pp.10705~9 (1993)
47. He Y, "Alternative splicing of vascular endothelial growth factor pre-mRNA is important for the regulation of VEGF activ-ity", 13, pp.537~545 (1999)
48. He H, "Vascular en-dothelial growth factor signals endothelial cell production of nitric oxide and prostacy-clin through flk-1", KDR activation of c-Src, 1999, pp.274, 25130~25135
49. Kabbinavar F, "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)", leuco- vorin (LV) with FU, pp.2003, 21[DOI]
50. Yang JC, "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer", 349, pp.427~434 (2003)
51. Eremina V, "Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and ac-quired renal diseases", 111, pp.707~716 (2003)
52. Tsatsaris V, "Over-expression of the soluble vascular endothelial growth factor receptor in preeclamptic patients:pathophysiological consequences", 88, pp.5555~5563 (2003)
53. Koga K, "Ele-vated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia", 88, pp.2348~2351 (2003)
54. Levine RJ, "Circu-lating angiogenic factors and the risk of preeclampsia", 350, pp.672~683 (2004)
55. Hertig A, "Ma-ternal serum sFltl concen- tration is an early and reliable predictive marker of preeclampsia", 50, pp.1702~1703 (2004)
56. Schlembach D, "Angiogenic fac-tors in preeclampsia", 10 (2003)
57. Powers RW, "Longitudinal analysis of serum sFlt-1 con-centrations in normal pregnancy and preeclampsia", 11 (2004)
58. Shibata E, "Serum level of soluble fms- like tyrosine kinase 1 is increased in preeclampsia but not in small for gestational age pregnancies", 11 (2004)
59. Chaiworapongsa T, "Evidence supporting a role for block-ade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award", 190, pp.1541~1547 (2004)
60. Thadhanni R, "First trimester placental growth factor and soluble fms-like tyrosine kinase l and risk for preeclampsia", 89, pp.770~775 (2004)
61. Torry DS, "Ex-pression and function of placenta growth factor:implications for abnormal placentation", 10, pp.178~188 (2003)
62. Torry DS, "preeclampsia is associated with reduced serum levels of placenta growth factor", 179, pp.1539~1544 (1998)
63. Taylor RN, "Longitudinal serum concentrations of placental growth factor:evidence for abnormal placental angioenesis in pathologic preg-nancies", 188, pp.177~182 (2003)
64. Reuvekamp A, "Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia", 106, pp.1019~1022 (1999)
65. Livingston JC, "Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia", 183, pp.1554~1557 (2000)
66. Livingston JC, "Placenta growth factor is not an early marker for the development of severe preeclampsia", 184, pp.1218~1220 (2001)
67. Tidwell SC, "Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia", 184, pp.1267~1272 (2001)
68. Bersinger NA, "Second_ and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies", 83, pp.37~45 (2004)
69. Chappell LC, "A lon-gitudinal study of biochemical variables in women at risk of preeclampsia", 187, pp.127~136 (2002)
70. Krauss T, "Prospective analysis of placenta growth factor concentrations in the plasma of wonmen with normal pregnancy and pregnancies complicated by preeclampsia", 23, pp.101~111 (2004)
71. Polliotti BM, "Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia", 101, pp.1266~1274 (2003)
72. Su YN, "Decreased maternal serum placenta growth factor in early second trimester and preeclampsia", 97, pp.898~904 (2001)
73. Ong CY, "First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction", 98, pp.608~611 (2001)
74. Thadhani R, "insulin resistance and alterations in angio-genesis:additive insults that may lead to preeclampsia", 43, pp.988~992 (2004)
75. Waite LL, "Preeclampsia, an implantation disorder", 3, pp.151~158 (2002)
76. Lyall F, "Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia", 104, pp.223~238 (1997)
77. Baker PN, "Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia", 86, pp.815~821 (1995)
78. Kupferminc MJ, "Vascular endothelial growth factor is in-creased in patients with preeclampsia", 38, pp.302~306 (1997)
79. Bosio PM, "Maternal plasma vascular endothelial growth factor concentrations in normal and hyper-tensive pregnancies and their relationship to peripheral vascular resistance", 184, pp.146~152 (2001)
80. Sharkey AM, "Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicsted by pre-eclampsia", 26, pp.1182~1185 (1996)
81. Kolben M, "Angioge-nin plasma levels during pregnancy", 176, pp.37~41 (1997)
82. Hirtenlehner K, "Elevated serum concentrations of the angiogenesis inhibitor endostatin in preeclam-ptic women", 10, pp.412~417 (2003)

관련 논문AI추천